Stoke Therapeutics plans $75M public offering on heels of Dravet trial results

The Bedford-based biotech ’s are trading at the highest point since October 2022 after it announced promising results from an early-stage trial of its drug for a rare, debilitating form of epilepsy that affects children.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news